Introduction
============

Colorectal cancer (CRC) is a malignant disease caused by a variety of factors involving with the accumulation of genetic and epigenetic changes. The incidence of CRC is increasing rapidly, and there are 1 million new CRC cases annually \[[@B1]\]. In the developed countries, the mortality of CRC has soared up to 33. CRC has become the second most common cancer in the world \[[@B2]\], accounting for 9 of all malignant tumors deaths \[[@B3]\]. Although 5-year survival rate of CRC patients has been improved from 22 to 47 in the last 30 years due to the advancement of the early diagnosis, surgical techniques and adjuvant therapies, the overall survival rate remains disappointing.

Abberrant expression of some important genes, such as *beta-catenin*\[[@B4]\], *SATB1*\[[@B5]\] and *EGFR*\[[@B6]\], were shown to be significantly associated with the occurrence and prognosis of CRC. Gene promoter hypermethylation often silences gene expression, while promoter hypomethylation tends to activate gene transcription. DNA methylation alteration has been considered as an important event in many malignancies including CRC.

Endothelin receptor type B (*EDNRB*) gene is located on 13q22, encoding a nonselective endothelin B receptor (ET~B~R) which belongs to a super-family of G-protein coupled receptor that mediates endothelins (ETs) \[[@B7]\]. ET~B~R is able to promote the production of neural crest cell-specific lineage, and thus it is related to the occurrence of Hirschsprung's disease \[[@B8]\] that is a blockage in the colon.

There are massive CpG dinucleotide repeats in the 5′-flanking region of *EDNRB* gene. The methylation of this CpG-riched region was shown to be able to regulate *EDNRB* gene expression \[[@B9]-[@B11]\]. Hypermethylation of *EDNRB* gene promoter has been observed in leukemia \[[@B12]\], oral cancer \[[@B13]\], skin cancer \[[@B14]\], head and neck cancer \[[@B15]\], melanoma \[[@B16]\], renal cell carcinoma \[[@B17]\], bladder cancer \[[@B18]\] and prostate cancer \[[@B19]\]. However, the function of *EDNRB* gene in CRC remains unknown. In light of previous findings in various cancers, we investigate whether *EDNRB* gene promoter methylation contributes to the risk of CRC in Chinese population.

Materials and methods
=====================

Tissue samples collection
-------------------------

Tumor and its normal adjacent tissue samples were collected at the time of surgery from 42 primary sporadic CRC patients in the Department of Gastrointestinal Surgery in Affiliated Hospital of Ningbo University between June 2012 and April 2013. Normal adjacent tissues were collected at least 5 cm away from the tumor. Tissues were stored in liquid nitrogen at -80°C immediately after excision. The diagnoses of all CRC cases were pathologically confirmed. None of CRC patients had received preoperative chemotherapy or radiation therapy. Tumor stage was determined according to the Duke's staging system, and cellular differentiation was graded according to the Broders' grading system. All the patients in the study have signed the informed written consent forms.

DNA isolation
-------------

Genomic DNA from tissue samples were extracted with QIAamp DNA Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer's instruction. Briefly, tissue sections were incubated with 180 μl of buffer ATL (in QIAamp DNA Mini Kit) and 20 μl of proteinase K on a thermostatic water bath at 56°C for 3 h, followed by incubation at 70°C for 10 min. Then, 200 μl of remixed Buffer AL (in QIAamp DNA Mini Kit) and ethanol (ratio 1:1) were added. Samples were mixed and transferred into QIAamp Mini spin columns. Centrifugation at 8,000 rpm for 1 min was followed by washing the spin column membrane with 500 μl of Buffer AW1 and 500 μl of Buffer AW2. DNA was eluted with 100 μl of Buffer AE. DNA concentration and quality were determined with spectrophotometer.

Bisulfite modification
----------------------

Eluted DNA was bisulphite-treated with ZYMO EZ DNA Methylation-Gold Kit according to the manufacturer's instruction (Zymo Research, Orange, CA, USA). The bisulphite-modified DNA was resuspended in 10 μl of TE buffer.

Methylation-specific PCR (MSP)
------------------------------

Methylation status of *EDNRB* promoter was determined by MSP. For the PCR reaction, 2 μl of modified DNA was amplified in a 20 μl reaction containing 0.3 μM each of forward and reverse primers, 0.2 mM dNTPs, 10 × PCR Buffer and 2.5 U of Hot Start DNA Polymerase (Qiagen, Hilden, Germany) under the following conditions: 15 min of denaturation at 95°C followed by 35 cycles of 45 s at 94°C, 45 s at 62°C for methylated primers, 1 min at 72°C and a final extension for 10 min at 72°C. The sequences of methylated and unmethylated primers were given in the previous study \[[@B20]\] (Table [1](#T1){ref-type="table"}). Water blank was used as a negative control. PCR products were subjected to 2.0 agarose gel electrophoresis at 100 V for 20 min, and visualized directly under UV illumination. Samples were considered as methylation or unmethylation, when there were clearly visible bands (130 or 134 bp) on the gel for methylation or unmethylation primers.

###### 

List of all primers used and conditions of PCR amplification

           **Primer**   **Sequence (5′-3′)**            **Product size (bp)**
  -------- ------------ ------------------------------- -----------------------
  M        F            CGAAGAGGTTGCGGGCGGTATTAGCG      130
           R            TACTCCAAAAACGTCCGATAACCG         
  U        F            TGGTGAAGAGGTTGTGGGTGGTATTAGTG   134
           R            ACCTACTCCAAAAACATCCAATAACCA      
  RT-PCR                                                 
           EDNRB-F      GAAAGCCTCCGTGGGAATC             86
           EDNRB-R      ACAGCTCGATATCTGTCAATACTCAGA      
           GAPDH-F      CCATGGAGAAGGCTGGGG              194
           GAPDH-R      CAAAGTTGTCATGGATGACC             

RNA isolation and reverse transcription
---------------------------------------

Total RNA was extracted from fresh frozen CRC and normal tissues from the same patients. RNA was extracted with TRIZOL reagent (Invitrogen Life Technologies Co, USA) according to the manufacturer's protocol. RNA concentration and quality were determined by NanoDrop ND-1000 (Thermal Fisher Scientific, USA). The first-strand cDNA was synthesized according to the manufacturer's instruction of M-MLV Reverse Transcriptase (Promega, Wisconsin, USA) with 2 μg DNase I-treated total RNA and 2 μM Oligo (dT)~15~ primer in a 20 μL volume.

qRT-PCR
-------

Primers for qRT-PCR were listed in Table [1](#T1){ref-type="table"}\[[@B21]\]. The qRT-PCR reactions were conducted in a 96-well plate using ABI7500 Real-Time system (Applied Biosystems, CA, USA). Each reaction was performed in triplicate and in a 20 μL volume containing 2× real-time PCR Master Mix with SYBR Green dye (Promega, Wisconsin, USA), 0.4 μM of each primer and 4 μL cDNA, using the following thermal conditions: 95°C for 10 min, followed by 40 cycles of 95°C for 15 s, 60°C for 1 min and 72°C for 40 s. A melting curve analysis from 60°C to 95°C was performed at the end of each PCR to further confirm the specificity of amplicons. *GAPDH* was used as an endogenous control. The Ct values displayed by the instrument were recorded. Samples were confirmed whether there was a clearly visible band (86/194 bp) on the gel with *EDNRB* or *GAPDH* primers (Figure [1](#F1){ref-type="fig"}).

![***EDNRB*and*GAPDH*mRNA expression in CRC tumor tissue.**](1746-1596-8-199-1){#F1}

Statistics
----------

Statistical analysis was performed by the SPSS statistical package (version 16.0; SPSS, Chicago, IL, USA) and the results were presented using GraphPad prism software. Comparisons of *EDNRB* promoter methylation were performed by the correction formula of Chi-square test. The 2^--ΔCt^ method was used to analyze the result of qRT-PCR. Two groups of related data were analyzed using paired t-test. The Mann-Whiteney U test was used for two groups of independent data which did not meet normality test. All analyses were two-sided, and p \< 0.05 was considered statistically significant.

Results
=======

Hypermethylated *EDNRB* promoter in CRC
---------------------------------------

To determine methylation of *EDNRB* gene, MSP was performed on 42 CRC and 42 adjacent normal tissues in the primary sporadic CRC patients. The representative agarose gel electrophoresis results were shown in Figure [2](#F2){ref-type="fig"}. Methylation status was determined when there were methylated bands in the gel. And unmethylation status was determined if both the methylated and unmethylated bands were not detected, For the unmethylated samples, we repeated the relative experiment two times, including testing the DNA quality, bisulphite modification and MSP (confirming PCR primers quality and PCR conditions). If the methylated and unmethylated bands still did not detect, we confirmed the status of the sample as unmethylation. Our study showed that hypermethylation of *EDNRB* in CRC tissues was more frequently than in corresponding normal tissues (92.86 versus 59.52, p = 0.001, Table [2](#T2){ref-type="table"}).

![**Representative results for methylation status of*EDNRB*gene in CRC tumor tissues (T) and adjacent normal tissues (N).**](1746-1596-8-199-2){#F2}

###### 

**Methylation status of*EDNRB*gene in CRC and normal tissues**

              **Total**   **M**   **U**   **M%**   **χ**^**2**^   **p value**
  ----------- ----------- ------- ------- -------- -------------- -------------
  CRC cases   42          39      3       92.86    11.091         0.001
  Controls    42          25      17      59.52                    

Correlation of *EDNRB* methylation with clinicopathological characteristics
---------------------------------------------------------------------------

The relationship between methylation status of *EDNRB* gene and the clinicopathological characteristics of CRC was shown in Table [3](#T3){ref-type="table"}. There was no significant difference in clinicopathological factors such as gender, age, TNM stages, lymph node status, metastasis status, tumor location, differentiation status, tumor size, and histological grade. There was no correlation of *EDNRB* gene methylation status with the serum levels of carcinoembryonic antigen (CEA) and carbohydrate antigen 19--9 (CA19-9).

###### 

Association between the EDNRB methylation in CRC serum and clinicopathologicalfeatures

                                                                  **EDNRB Methylation**                 
  ----------------------------- ---------------------------- ---- ----------------------- --- --------- -------
  Gender                        Male                         28   27                      1   0.404     0.525
                                Female                       14   12                      2              
  Age(year)                     ≤60                          16   16                      0   0.629     0.428
                                \>60                         26   23                      3              
  Stage                         1/2                          21   18                      3   1.436     0.231
                                3/4                          21   21                      0              
  Lymph metastasis              Yes                          21   21                      0   1.436     0.231
                                No                           21   18                      3              
  Distant metastasis            Yes                          8    8                       0   0.012     0.913
                                No                           34   31                      3              
  CEA                           ≥5.0 ng/ml                   15   14                      1   \<0.001   1
                                \<5.0 ng/ml                  27   25                      2              
  CA19-9                        ≥37U/ml                      9    8                       1   \<0.001   1
                                \<37U/ml                     33   31                      2              
  Tumor location                Colon                        26   24                      2   \<0.001   1
                                Rectum                       16   15                      1              
  Differentiation               Poor                         10   10                      0   0.091     0.763
                                Moderate                     32   29                      3              
                                Well                         0    0                       0              
  Tumor size                    \<5 cm                       28   25                      3   0.404     0.525
                                ≥5 cm                        14   14                      0              
  Histological classification   Adenocarcinoma               40   37                      3   \<0.001   1
                                Mucinous adenocarcinoma      2    2                       0              
                                Undifferentiated carcinoma   0    0                       0              

*EDNRB* expression is down-regulated in CRC tissues
---------------------------------------------------

We determined *EDNRB* mRNA expression in 42 CRC tissues and 42 adjacent normal colorectal tissues by qRT-PCR. The gene expression level of *EDNRB* was normalized with the values of the control gene *GAPDH*. Our results showed that *EDNRB* mRNA level in CRC tumor samples was significantly lower than in their adjacent normal samples (0.31 ± 0.91 versus 0.70 ± 1.18, p = 0.032, Figure [3](#F3){ref-type="fig"}, Table [4](#T4){ref-type="table"}).

![**Expression level of*EDNRB*gene in CRC tumor tissues (T) and adjacent normal tissues (N).** RT-qPCR was used to analyze the expression level of *EDNRB* gene in CRC tumor tissues and adjacent normal tissues. The relative expression of *EDNRB* mRNA level was significantly higher in normal tissues than that in CRC tumor tissues (p = 0.032).](1746-1596-8-199-3){#F3}

###### 

***EDNRB*mRNA expression levels in CRC and normal tissues\***

            **Total**   **Mean**   **SD**   **SE**   **t**    **p value**
  --------- ----------- ---------- -------- -------- -------- -------------
  CRC       42          0.3074     0.91     0.14     -2.214   0.032
  Control   42          0.7041     1.18     0.18               

\*: SD denotes standard deviation and SE denotes standard error.

Correlation of *EDNRB* expression status with clinicopathological characteristics
---------------------------------------------------------------------------------

We further examined the relationship between *EDNRB* mRNA expression and clinicopathological characteristics (Table [5](#T5){ref-type="table"}). There was no significant correlation between *EDNRB* expression and the clinicopathological factors such as gender, age, TNM stages, lymph node status, metastasis status, tumor location, differentiation status, tumor size, and histological classification.

###### 

**Correlation of*EDNRB*mRNA expression and clinicopathological parameters of colorectal cancer samples\***

                                                                  ***EDNRB*expression relative to*GAPDH***                   
  ----------------------------- ---------------------------- ---- ------------------------------------------ ------- ------- -------
  Gender                        Male                         28   0.336                                      1.073   0.202   0.722
                                Female                       14   0.250                                      0.480   0.130    
  Age (year)                    ≤60                          16   0.221                                      0.444   0.111   0.836
                                \>60                         26   0.360                                      1.114   0.218    
  Stage                         1/2                          21   0.143                                      0.233   0.051   0.792
                                3/4                          21   0.472                                      1.257   0.281    
  Lymph metastasis              Yes                          21   0.457                                      1.266   0.276   0.95
                                No                           21   0.158                                      0.238   0.052    
  Distant metastasis            Yes                          8    0.781                                      1.996   0.706   0.741
                                No                           34   0.196                                      0.351   0.060    
  CEA                           ≥5.0 ng/ml                   15   0.121                                      0.156   0.040   0.723
                                \<5.0 ng/ml                  27   0.411                                      1.127   0.217    
  CA19-9                        ≥37U/ml                      9    0.102                                      0.153   0.051   0.526
                                \<37U/ml                     33   0.364                                      1.023   0.178    
  Tumor location                Colon                        26   0.428                                      1.145   0.225   0.351
                                Rectum                       16   0.112                                      0.156   0.039    
  Differentiation               Poor                         10   0.719                                      1.779   0.558   0.494
                                Moderate                     32   0.179                                      0.341   0.062    
                                Well                         0    /                                          /       /        
  Tumor size                    \<5 cm                       28   0.386                                      1.102   0.208   0.968
                                ≥5 cm                        14   0.151                                      0.248   0.066    
  Histological classification   Adenocarcinoma               40   0.315                                      0.935   0.148   0.455
                                Mucinous adenocarcinoma      2    0.162                                      0.157   0.111    
                                Undifferentiated carcinoma   0    /                                          /       /        

\*: SD denotes standard deviation and SE denotes standard error.

Discussion
==========

Cancer development and progression may be contributed by both genetic and epigenetic factors. As one of the major epigenetic modifications, DNA methylation of promoter often down-regulates gene transcription. A growing number of evidences show that DNA methylation mediated tumor suppressor gene silencing may contribute to tumor progression \[[@B22]-[@B24]\]. Aberrant DNA methylated loci have become promising biomarkers in the early diagnosis of diseases \[[@B25],[@B26]\].

EDNRB is a G protein--coupled receptor that activates a phosphatidylinositol-calcium second messenger system. The product of *EDNRB* gene (ET~B~ receptor, ET~B~R) is able to bind to endothelins (ETs), consisting of a family of 3 potent vasoactive peptides (ET1, ET2, and ET3) \[[@B13]\]. During the development of tumor, *EDNRB* gene transcription is downregulated by promoter hypermethylated, and consequently alters the ET1 signaling pathway \[[@B27]\]. Disruption in the ET1 signaling pathway has been shown to be involved in a variety of human tumor proliferation, angiogenesis, and metastasis \[[@B28]-[@B30]\]. *EDNRB* gene silencing by promoter hypermethylation has been reported in a variety of tumors such as leukemia, oral cancer, skin cancer, head and neck cancer, melanoma, renal cell carcinoma, bladder cancer, and prostate cancer \[[@B12]-[@B19]\]. Our study in CRC adds a new piece of evidence for the contribution of *EDNRB* promoter hypermethylation to the risk of CRC. Our results further confirmed that DNA methylation in the promoter region played a key role in *EDNRB* transcription.

Some reports have focused on the correlation between *EDNRB* methylation and cancer clinical features \[[@B31]-[@B33]\]. Hypermethylation of the *EDNRB* gene in paired gastric cancer tissues and adjacent normal tissues from 96 patients was detected \[[@B32]\]. *EDNRB* gene promoter methylation was shown to be associated with gastric cancer tumor invasion \[[@B32]\]. The extent of hypermethylation at CpG island in *EDNRB* gene was also evaluated in seven prostate cancer cell lines, normal prostate epithelial cells, normal prostate stromal cells, 73 primary prostate cancers, 91 metastatic prostate cancers, and 25 noncancerous prostate tissues \[[@B33]\]. *EDNRB* CpG island hypermethylation was shown to be correlated with pathological stage and Gleason score to a statistically significant extent in prostate cancer \[[@B33]\]. In the present study, we examined the relationship between the *EDNRB* methylation and the clinical features. Unfortunately, there was no significant relationship between *EDNRB* methylation or expression status and the clinical features. And this may be due to a lack of power in our samples. As a kind of glycoprotein produced by colorectal cancer tissue, CEA is a good tumor marker for judging efficacy, disease progression, and prognosis of colorectal cancer. CA19-9 was frequently increased in gastrointestinal tumors such as pancreatic cancer, gastric cancer, and colorectal cancer. CEA and CA19-9 are commonly and traditionally used in clinical colorectal cancer detection. Our study showed no correlation of *EDNRB* gene methylation status with the serum levels of CEA and CA19-9. This might imply that aberrant *EDNRB* methylation and conventional tumor markers could serve as complementary markers in the CRC diagnosis, although further work is needed to confirm our hypothesis.

In conclusion, we revealed a significant contribution of *EDNRB* hypermethylation to the risk of CRC. These findings may provide a new clue for detection and treatment of CRC. Future research is needed to determine the detailed mechanism of *EDNRB* gene in the risk of CRC.
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